Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration

Cornea

Volumn 29, Issue 8, 2010, Pages 849-852

  Pérez Rico, Consuelo ^a   Benítez Herreros, Javier ^a   Castro Rebollo, María ^a   Gómez Sangil, Yanira ^a   Germain, Francisco ^b   Montes Mollón, María Ángeles ^a   Teus, Miguel Ángel ^a  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

age related macular degeneration; corneal endothelium; ranibizumab; specular microscopy; vascular endothelial growth factor A

Indexed keywords

DEXAMETHASONE PLUS TOBRAMYCIN; RANIBIZUMAB; MONOCLONAL ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AGING; ARTICLE; CORNEA ENDOTHELIUM; CORNEA THICKNESS; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REPEATED DRUG DOSE; RETINA; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME; VISUAL ACUITY; CELL COUNT; CELL SIZE; DRUG EFFECTS; INJECTION; MACULAR DEGENERATION; MICROSCOPY; MIDDLE AGED; PATHOLOGY; VERY ELDERLY; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CELL COUNT; CELL SIZE; ENDOTHELIUM, CORNEAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MICROSCOPY; MIDDLE AGED; PROSPECTIVE STUDIES; VITREOUS BODY; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77955172318     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181ca33d2     Document Type: Article

References (24)

1. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111-118.
2. Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005;293: 1509-1513.
3. Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85:425-430.
4. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-733.
5. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
6. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004; 82:557-563.
7. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
8. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977-982.
9. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993-997.
10. Schultz RO, Matsuda M, Yee RW, et al. Corneal endothelial changes in type I and type II diabetes mellitus. Am J Ophthalmol. 1984;98:401-410.
11. Geroski DH, Edelhauser HF. Morphometric analysis of the corneal endothelium. Specular microscopy vs. alizarin red staining. Invest Ophthalmol Vis Sci. 1989;30:254-259.
12. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophth almol. 2007;245:1837-1842.
13. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90:1316-1321.
14. Luke M, Warga M, Ziemssen F, et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol. 2006;90:1178-1182.
15. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina. 2006;26:512-518.
16. Iriyama A, Chen YN, Tamaki Y, et al. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol. 2007;91:1230-1233.
17. Kernt M, Welge-Liissen U, Yu A, et al. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe. 2007;104: 965-971.
18. Chen YN, Tamaki Y, Yanagi Y. Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol. 2007;91:1230-1233.
19. Maturi RK, Bleau LA, Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:270-274.
20. Manzano RP, Peyman GA, Khan P, et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257-261.
21. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-269.
22. Chiang CC, Chen WL, Lin JM, et al. Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study. Am J Ophthalmol. 2008;146:688-691.
23. Rainer G, Petternel V, Findl O, et al. Comparison of ultrasound pachymetry and partial coherence interferometry in the measurement of central corneal thickness. J Cataract Refract Surg. 2002;28:2142-2145.
24. Perez-Rico C, Benitez-Herreros J, Castro-Rebollo M, et al. Endothelial cell analysis after intravitreal ranibizumab (Lucentis) in age-related macular degeneration treatment: a pilot study. Br J Ophtalmol. 2009;94:1-1